- Conditions
- Acute Myeloid Leukemia
- Interventions
- SAR443579, venetoclax, azacitidine
- Biological · Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Duarte, California • The Bronx, New York • Columbus, Ohio + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
Recognized from query: venetoclax. Matching terms were moved into the structured fields above when recognized.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 465
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia (AML), Cancer
- Interventions
- Venetoclax, Azacitidine, Decitabine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 16
- States / cities
- Tempe, Arizona • Denver, Colorado • Lone Tree, Colorado + 12 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
- Interventions
- Venetoclax, Fludarabine, Busulfan, Azacitidine, Decitabine/cedazuridine
- Drug
- Lead sponsor
- Jacqueline Garcia, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Lemzoparlimab, Azacitidine, Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Louisville, Kentucky • Boston, Massachusetts + 5 more
- Conditions
- Diffuse Large B-cell-lymphoma
- Interventions
- Venetoclax, Rituximab, Ifosfamide, Carboplatin, Etoposide
- Drug
- Lead sponsor
- Molly Gallogly
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Cleveland, Ohio
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myeloid Neoplasm, Relapsed Acute Biphenotypic Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Mixed Phenotype Acute Leukemia, Relapsed Myeloid Neoplasm, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myeloid Neoplasm, Recurrent Myeloid Sarcoma
- Interventions
- Cladribine, Cytarabine, Mitoxantrone, Recombinant Granulocyte Colony-Stimulating Factor, Venetoclax, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection
- Drug · Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Myeloid Leukemia
- Interventions
- MBG453, Venetoclax, Azacitidine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Iowa City, Iowa + 8 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Venetoclax, Rituximab, Rituximab/Hyaluronidase Human
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey
- Conditions
- Recurrent AL Amyloidosis, Refractory AL Amyloidosis
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Dexamethasone, Echocardiography Test, Ixazomib Citrate, Magnetic Resonance Imaging, Positron Emission Tomography, Transabdominal Ultrasound, Venetoclax, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 16
- States / cities
- Duarte, California • Sacramento, California • Atlanta, Georgia + 10 more
- Conditions
- AML (Acute Myeloid Leukemia)
- Interventions
- CLN-049, Azacitidine, Venetoclax
- Drug
- Lead sponsor
- Cullinan Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Duarte, California • Miami, Florida • Atlanta, Georgia + 2 more
- Conditions
- AL Amyloidosis
- Interventions
- Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Interventions
- SEA-CD70, azacitidine, Venetoclax
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Magrolimab, Venetoclax, Azacitidine, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 39
- States / cities
- Little Rock, Arkansas • Duarte, California • Fresno, California + 31 more
- Conditions
- Multiple Myeloma
- Interventions
- Venetoclax, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Columbus, Georgia • Fairway, Kansas • St Louis, Missouri + 2 more
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- Venetoclax, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Venetoclax, Cyclophosphamide, Obinutuzumab, Rituximab, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 9
- States / cities
- Fullerton, California • Los Angeles, California • Santa Maria, California + 6 more
- Conditions
- Acute Monocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cladribine, Cytarabine, Echocardiography, Lumbar Puncture, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax
- Drug · Procedure · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Miami, Florida • Portland, Oregon
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 634
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more
- Conditions
- Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Decitabine, Navitoclax, Venetoclax
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leukemia, Myeloid
- Interventions
- CC-90011, Venetoclax, Azacitidine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 11
- States / cities
- Duarte, California • New Haven, Connecticut • Miami, Florida + 8 more
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- Venetoclax
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Myeloid Leukemia
- Interventions
- Fludarabine, Cytarabine, Idarubicin, Filgrastim, Venetoclax, Asciminib, Blinatumomab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- ABT-199, Rifampin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey